Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Greenberg

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disordersMaureen A Mealy, Su-Hyun Kim, Felix Schmidt, et al.
Plos One|April 8, 2016
A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCRBenjamine Arellano, Rehana Hussain, William A Miller-Little, et al.
Multiple Sclerosis and Related Disorders|April 27, 2025
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims dataBenjamin M Greenberg, Kazuo Fujihara, Brian Weinshenker, et al.
Vaccine|July 13, 2025
SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient populationBenjamin M Greenberg, John D Minna, David E Gerber, et al.
Journal of Nanobiotechnology|December 13, 2023
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trialsJimin Ren, Richard B Dewey, Austin Rynders, et al.
Journal of Nanobiotechnology|January 3, 2024
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trialsJimin Ren, Richard B Dewey, Austin Rynders, et al.
The Lancet. Neurology|April 26, 2020
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 24, 2013
Elevated CNS inflammation in patients with preclinical Alzheimer's diseaseNancy L Monson, Sara J Ireland, Ann J Ligocki, et al.
Archives of Neurology|July 4, 2012
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis opticaBenjamine Arellano, Rehana Hussain, Tresa Zacharias, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 25, 2021
Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum DisorderJie Li, Sam A Bazzi, Florian Schmitz, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disordersMaureen A Mealy, Su-Hyun Kim, Felix Schmidt, et al.
Plos One|April 8, 2016
A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCRBenjamine Arellano, Rehana Hussain, William A Miller-Little, et al.
Multiple Sclerosis and Related Disorders|April 27, 2025
Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims dataBenjamin M Greenberg, Kazuo Fujihara, Brian Weinshenker, et al.
Vaccine|July 13, 2025
SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient populationBenjamin M Greenberg, John D Minna, David E Gerber, et al.
Journal of Nanobiotechnology|December 13, 2023
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trialsJimin Ren, Richard B Dewey, Austin Rynders, et al.
Journal of Nanobiotechnology|January 3, 2024
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trialsJimin Ren, Richard B Dewey, Austin Rynders, et al.
The Lancet. Neurology|April 26, 2020
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Benjamin M Greenberg, Jeffrey L Bennett, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|October 24, 2013
Elevated CNS inflammation in patients with preclinical Alzheimer's diseaseNancy L Monson, Sara J Ireland, Ann J Ligocki, et al.
Archives of Neurology|July 4, 2012
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis opticaBenjamine Arellano, Rehana Hussain, Tresa Zacharias, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 25, 2021
Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum DisorderJie Li, Sam A Bazzi, Florian Schmitz, et al.
Pageof 14